You have 9 free searches left this month | to do more

durvalumab

Durvalumab is a drug used to treat Hepatocellular Carcinoma, Breast Cancer, Non-small Cell Lung Cancer, and other conditions. Durvalumab is being actively studied in 290 studies and prior, has been studied in 30.

Top SponsorsTop SitesTop Investigators
AstraZenecaResearch SiteDo-Youn Oh
National Cancer Institute (NCI)M D Anderson Cancer CenterJong-Mu Sun
Canadian Cancer Trials GroupMemorial Sloan Kettering Cancer CenterZahi Mitri, MD, MS
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Not yet recruiting
  • Extensive-Stage Small-Cell Lung Cancer
  • durvalumab + anlotinib
  • Durvalumab
  • (no location specified)
2021-07-27
Jul 27, 2021
S
Recruiting
  • Unresectable Stage III NSCLC
  • Durvalumab
  • +4 more
  • Zhengzhou, Henan, China
  • +1 more
2021-08-01
Aug 1, 2021
S
Recruiting
  • Lung Cancer
  • +3 more
  • Durvalumab
  • +2 more
  • Detroit, Michigan
    Henry Ford Health System
2021-04-09
Apr 9, 2021
A
Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Durvalumab
  • low-dose PCI
  • Maastricht, Netherlands
    Maastro
2021-04-01
Apr 1, 2021
R
Active, not recruiting
  • Head and Neck Cancer
  • PD-L1 imaging
  • Durvalumab
  • Amsterdam, Netherlands
  • +3 more
2021-10-12
Oct 12, 2021
Z
Recruiting
  • Non Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center
2021-05-17
May 17, 2021
P
Recruiting
  • Non Small Cell Lung Cancer Stage III
  • Small-Cell Lung Cancer
  • Durvalumab
  • Beijing, China
    Peking Union Medical College Hospital
2020-12-11
Dec 11, 2020
W
Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Durvalumab
  • Durvalumab plus SBRT
  • New York, New York
    Weill Cornell Medicine
2021-08-04
Aug 4, 2021
B
Recruiting
  • Limited Stage Small Cell Lung Cancer
  • Durvalumab
  • Beijing, China
    Beijing Haidian Hospital
2021-09-01
Sep 1, 2021
Y
Recruiting
  • Stage II-IVB Operable HNSCC Oral Cavity
  • +3 more
  • Durvalumab
  • durvalumab + tremelimumab
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
2021-04-22
Apr 22, 2021
U
Not yet recruiting
  • Small-cell Lung Cancer
  • +2 more
  • Ablative Radiation
  • +3 more
  • (no location specified)
2021-09-24
Sep 24, 2021
S
Recruiting
  • Bile Duct Cancer
  • Chemotherapy Effect
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2021-09-22
Sep 22, 2021
D
Suspended
  • Mesothelioma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-03-30
Mar 30, 2021
T
Recruiting
  • Hepatocellular Carcinoma
  • Durvalumab
  • Stereotactic body radiation therapy
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Queen Mary Hospital
2021-05-28
May 28, 2021
D
Active, not recruiting
  • Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2021-09-22
Sep 22, 2021
U
Not yet recruiting
  • Bladder Cancer
  • Durvalumab
  • S-488210/S-488211
  • (no location specified)
2021-05-04
May 4, 2021
T
Recruiting
  • Breast Cancer
  • Durvalumab
  • +2 more
  • Houston, Texas
    Houston Methodist Cancer Center
2021-07-16
Jul 16, 2021
S
Active, not recruiting
  • Hepatocellular Carcinoma
  • Durvalumab
  • Radioembolization
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2021-09-23
Sep 23, 2021
H
Recruiting
  • Stage III Non-small-cell Lung Cancer
  • Durvalumab
  • SBRT
  • Providence, Rhode Island
  • +1 more
2021-07-09
Jul 9, 2021
D
Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Boston, Massachusetts
  • +1 more
2021-08-30
Aug 30, 2021
G
Active, not recruiting
  • Non Small Cell Lung Cancer
  • Stage III Non-small-cell Lung Cancer
  • Durvalumab
  • +4 more
  • Chicago, Illinois
  • +3 more
2021-07-26
Jul 26, 2021
F
Not yet recruiting
  • Hepatocellular Carcinoma
  • Durvalumab
  • +2 more
  • (no location specified)
2021-04-30
Apr 30, 2021